Professional
Added to YB: 2026-06-03
Pitch date: 2026-04-09
DFTX [bullish]
Definium Therapeutics, Inc.
+3.89%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders.
Market Cap
$2.6B
Pitch Price
$22.00
Price Target
49.00 (+103%)
Dividend
N/A
EV/EBITDA
N/A
P/E
-9.65
EV/Sales
N/A
Sector
Pharmaceuticals
Category
growth
Show full summary:
Definium Therapeutics, Inc. (DFTX) - Initiate At Overweight: A Long Overdue New Approach To Anxiety And Mood
DFTX: Piper Sandler initiates Overweight, PT $49 (~137% upside from $21). DT120, oral LSD tablet for GAD/MDD, best-in-class neuroplastogen. Ph IIb HAM-A -7.7 vs placebo wk12 (vs Cymbalta ~3). Peak US sales >$3B. PT=25x 2031E EBITDA $421M. Ph III GAD/MDD readouts 2Q26-2H26. Risks: clinical, Schedule I regulatory, IP, commercialization.